TransCode Therapeutics
RNAZ | NASDAQ
$1.35
+$0.03 (+2.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.37
+$0.02 (+1.48%)
After-hours:
Nov 16, 2026, 7:30 PM ET
TransCode Therapeutics Company Profile
Company profile explainedCompany Profile
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Philippe Calais | Chief Executive Officer & Executive Chairman of the Board |
| John A. Tattory | Interim Chief Financial Officer |
| Anna Moore | Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board |
| Daniel R. Vlock | Chief Medical Officer |
| Michel Janicot | Consulting Head of Translational Science |
| Susan Duggan | Senior Vice President of Operations |
| Thomas A. Fitzgerald | CFO, Secretary, President, VP of Administration & Director |
| Zdravka Medarova | Scientific Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 3 | Filing |
| Sep 11, 2026 | 4 | Filing |
| Sep 11, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 3 | Filing |
| Aug 03, 2026 | SC 13D/A | [Amend] Filing |
TransCode Therapeutics
| Country | United States |
| IPO Date | Jul 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Philippe Calais |
Contact Details
6 Liberty Square Boston,
Massachusetts 02109 United States
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001829635 |
| CUSIP Number | 89357L501 |
| ISIN Number | US89357L5012 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove RNAZ